J. Schlaak

发表

MicroRNA‐155 controls Toll‐like receptor 3‐ and hepatitis C virus‐induced immune responses in the liver

G. Gerken, E. Zhang, X. Zhang, 2014, Journal of viral hepatitis.

Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B.

G. Gerken, K. Meyer zum Büschenfelde, T. Wölfel, 2008, Liver.

[Impressive picture of a melanosis coli after chronic anthraquinone laxative use--is there an increased risk for colorectal cancer?].

J. Langhorst, R. Klein, K. Metz, 2009, Zeitschrift fur Gastroenterologie.

Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology.

G. Gerken, H. Dienes, B. Fleischer, 2008, Liver.

Liver-infiltrating and circulating CD4+ T cells in chronic hepatitis C: immunodominant epitopes, HLA-restriction and functional significance.

G. Gerken, H. Dienes, K. Meyer zum Büschenfelde, 2008, Liver.

Autoreactive CD4+ LKM‐specific and anticlonotypic T‐cell responses in LKM‐1 antibody‐positive autoimmune hepatitis

G. Gerken, A. Lohse, J. Schlaak, 1996, Hepatology.

Hepatitis G virus: an old, but newly discovered hepatotropic virus--is it of interest for the nephrologist?

H. Köhler, J. Schlaak, G. Gerken, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Hepatitis B virus particles activate toll-like receptor 2 signaling initial upon infection of primary human hepatocytes

G. Gerken, A. Paul, M. Trippler, 2019, 35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber.

Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infection

P. Schirmacher, G. Gerken, H. Dienes, 1994, The clinical investigator.

Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge.

G. Gerken, P. Knolle, K. Meyer zum Büschenfelde, 1995, Journal of hepatology.

CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon‐α therapy and toll‐like receptor 3 signalling

R. Lempicki, M. Polis, G. Gerken, 2012, Journal of viral hepatitis.

Hepatic expression of proteasome subunit alpha type‐6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin‐like modifier, a proviral host gene in hepatitis C virus infection

B. Sitek, G. Gerken, M. Eisenacher, 2016, Journal of viral hepatitis.

Microarrays-Enabled Hypothesis Generation: The Suspect Role of FNBP-1 in Neuropsychiatric Pathogenesis Associated with HIV and/or HCV Infection

G. Gerken, A. Katsounas, J. Schlaak, 2016, Journal of AIDS & clinical research.

IFN‐α subtypes: distinct biological activities in anti‐viral therapy

U. Dittmer, D. Yang, J. Schlaak, 2013, British journal of pharmacology.

Toll‐like receptor‐mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen

G. Gerken, Mengji Lu, M. Trippler, 2014, Journal of viral hepatitis.

Interleukin‐2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon‐α plus ribavirin

G. Gerken, A. Barreiros, J. Schlaak, 2003, European journal of clinical investigation.